Aytu reports Q1 fiscal 2027 results amid pending Rosemont acquisition
Aytu BioPharma posted higher net revenue on EXXUA growth while disclosing a definitive merger agreement with Rosemont Pharmaceuticals Holdings for $2.70 per share in cash.
Aytu BioPharma announced on November 16, 2026 that it has entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc., under which Rosemont would acquire Aytu through a cash tender offer of $2.70 per share, followed by a merger, with total consideration of roughly $56 million on a fully diluted basis using the treasury stock method.1 The company said it expects the deal to close by the end of calendar 2026, pending customary closing conditions, including tender of a majority of Aytu's outstanding common shares.1 Because of the pending transaction, Aytu will not hold an earnings conference call to discuss the quarter.1
For the fiscal 2027 first quarter ended September 30, 2026, net revenue rose 6.9% to $14.8 million from $13.9 million a year earlier.1 The gain was driven by EXXUA, the company's antidepressant: EXXUA net revenue reached $4.9 million, up 24.5% from $3.9 million in the fiscal 2026 fourth quarter, with total prescriptions climbing 32.5% sequentially to 4,400 for the quarter and a September 2026 monthly peak near 1,650 scripts.1
Other portfolios moved in opposite directions. ADHD portfolio revenue fell to $7.7 million from $13.2 million a year earlier, which Aytu attributed to lighter promotional spending as resources shifted to EXXUA and to generic competition for Adzenys XR-ODT.1 Pediatric portfolio revenue rose to $2.2 million from $0.7 million, helped by better payer mix and fewer returns, particularly in the multivitamin line.1
On profitability, the company posted a net loss of $3.9 million, or $0.20 per share, compared with net income of $2.0 million a year earlier, a swing driven in part by a smaller non-cash derivative warrant gain of $0.3 million versus $3.8 million.1 Adjusted EBITDA was negative $2.6 million versus negative $0.6 million, reflecting continued investment in EXXUA's commercial launch.1 Cash and equivalents stood at $25.5 million as of September 30, 2026, down from $26.3 million at the end of the prior quarter.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.